Welcome to the 3rd Annual B & T Cell-Mediated Autoimmune Disease
Drug Development Summit
The definitive industry forum for drug developers investing in immune modulation strategies in autoimmune diseases
This Summer, join a community of 80+ industry pioneers from large pharma, biotech, and academia, advancing the discovery, development, optimization, and strategizing the new generation of treatments in the B & T Cell-Mediated Autoimmune Diseases space.
The cross-disciplinary program has been curated alongside experts including Pfizer, Eli Lilly & Co, Kymera Therapeutics, Regeneron, and many more. Covering topics from autoantigen specific B cell depleting and modulating therapies (CAART, BTK inhibitors, anti-CD20), targeting T cell co-stimulatory pathways (CD40/CD40L, CD28/CTLA-4, OX40, ICOS, PD-1), and subduing autoantibodies (FcRn inhibitors and beyond), this is a conversation not to miss.
Don’t miss this exciting opportunity to get your critical questions answered to supercharge your clinical programs, give direction to your drug pipelines and ensure the next generation of B & T cell-directed therapies can improve treatment regimens in chronic, common, and rare autoimmune diseases.
View our full event guide to see our complete speaker line-up, latest agenda, and attending audience.
Hear What Your Colleagues Have Said:
‘Excellent breadth and depth of the program to allow participants gain in
depth knowledge of cutting-edge research in the autoimmune field’
‘A great conference with plenty of opportunity to learn innovative science
and approaches target autoimmune diseases’
Your 2022 Expert Speaker Faculty Includes
Immune Tolerance Lead, Inflammation & Immunology
Professor of Microbiology- Immunology
Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics
Duke University Medical Centre
2021 Attending Companies Included:
Proud to Partner With:
“The program has a fine balance of comprehensive topic areas whilst not compromising focus on how our knowledge of the roles of B and T cells in autoimmune disease pathogenesis could serve to identify novel biomarkers and therapeutic strategies”
University College London